Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability—Brief Report
Mice, Knockout
Male
0303 health sciences
Membrane Glycoproteins
Basic Sciences
Cell Survival
Aortic Diseases
Atherosclerosis
Diet, High-Fat
Plaque, Atherosclerotic
Mice, Inbred C57BL
Disease Models, Animal
Mice
Necrosis
03 medical and health sciences
Receptors, LDL
Animals
Receptors, Immunologic
Foam Cells
Cell Proliferation
DOI:
10.1161/atvbaha.124.320797
Publication Date:
2024-05-02T09:00:41Z
AUTHORS (16)
ABSTRACT
BACKGROUND: Trem2 (triggering receptor on myeloid cells 2), a surface lipid receptor, is expressed foamy macrophages within atherosclerotic lesions and regulates cell survival, proliferation, anti-inflammatory responses. Studies examining the role of in atherosclerosis have shown that deletion leads to impaired macrophage uptake, cholesterol efflux. Thus, we tested hypothesis administration agonist antibody (AL002a) atherogenic mice would enhance survival decrease necrotic core formation improve plaque stability. METHODS: To model therapeutic intervention approach, atherosclerosis-prone (Ldlr [low-density lipoprotein receptor] −/− ) were fed high-fat diet for 8 weeks, then transitioned treatment with AL002a or isotype control an additional weeks while continuing diet. RESULTS: AL002a-treated had increased lesion size both aortic root whole mount aorta, which correlated expansion area. This was due proliferation plaques. Importantly, plaques from showed improved features stability, including smaller cores, fibrous caps, greater collagen deposition. Single-cell RNA sequencing aorta suspensions isotype- revealed agonism dramatically altered transcriptome. included upregulation oxidative phosphorylation expression genes. In vitro studies validated promoted oxidized low-density CONCLUSIONS: expands by promoting but improves stability rewiring function efflux
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (44)
CITATIONS (17)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....